Logo
Login
$LONA
$4.76 -$0.08 (1.65%) Close

Company Executives

$LONA Management Team

Dr. Mark Litton

President

Chief Executive Officer

Director

Age 57
Compensation $1.424M USD
Sex Male

Ms. Kelly Romano

Independent Chairwoman of the Board

Age 63
Compensation $90.66K USD
Sex Female

Ms. Julie Rathbun

Investor Relations

Age -
Compensation -
Sex Female

Dr. Kevin Church

Chief Scientific Officer

Age 40
Compensation $1.336M USD
Sex Male

Mr. Robert Renninger

Chief Financial Officer

Age 41
Compensation -
Sex Male

Mr. Mark Worthington

Chief Compliance Officer

General Counsel

Company Secretary

Age 59
Compensation $731.5K USD
Sex Male

Dr. Javier San Martin

Chief Medical Officer

Age 60
Compensation $810.1K USD
Sex Male

Board of Directors

From the proxy statement filed May 11, 2026
Directors
10
serving now
Independent
9 of 10
stated in the proxy
Average tenure
3.6 years
from year joined
CEO also chairs the board
No
Kelly A. Romano
Director Age On board Independent Committees Other public boards 2025 pay Source
Kelly A. Romano
Board chair
 64 2020
6 years
 Independent
Nominating and Corporate Governance · Chair
UGI Corporation, Dorman Products, Inc., Potter Global Technologies $90,657
James A. Johnson
69 2020
6 years
 Independent
Audit · Chair
None stated $70,157
Natalie C. Holles
53 2026
0 years
 Independent None stated Aura Biosciences Not stated
Frederick P. Callori
58 2026
0 years
 Independent None stated None stated Not stated
Joseph Edelman
70 2020
6 years
 Independent None stated Perceptive Capital Solutions Corp. $49,157
Grant Pickering
58 2022
4 years
 Independent None stated Vaxcyte, Inc. $50,157
Peter B. Silverman
48 2026
0 years
 Independent None stated Kinaset Therapeutic Not stated
Barbara Kosacz
68 2021
5 years
 Independent
Compensation · Chair
XOMA Royalty Corporation $59,157
Mark Litton
CEO
 58 2021
5 years
 Not independent None stated None stated Paid as CEO
Michael Panzara
59 2022
4 years
 Independent
Compliance · Chair
None stated $59,157

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

5 disclosed in the proxy filed May 11, 2026
Perceptive Life Sciences Master Fund Ltd.
greater than 5% holder of our common stock prior to the PIPE Transaction; Joseph Edelman, a director, is a managing member of its investment manager
$20.0 million
December 18, 2025

Purchased common stock, pre-funded warrants and Series A and Series B common warrants in the PIPE private placement, together with Perceptive Xontogeny Venture Fund II, LP, for an aggregate purchase price of $20.0 million

Open in proxy
Peter B. Silverman
designated to our board of directors by Commodore under the PIPE Securities Purchase Agreement
Amount not stated

Board designation right under the PIPE Securities Purchase Agreement; designee appointed to our board of directors

With Commodore Open in proxy
Natalie C. Holles
designated to our board of directors by TCGX under the PIPE Securities Purchase Agreement
Amount not stated

Board designation right under the PIPE Securities Purchase Agreement; designee appointed to our board of directors

With TCGX Open in proxy
Sermonix Pharmaceuticals, Inc.
an affiliate of Perceptive Advisors held approximately 29% of the outstanding capital stock of Sermonix at the time of entry into the Sermonix License
Approximately $16.8 million
December 18, 2025

Exclusive license to develop and commercialize oral lasofoxifene outside Asia and certain Middle East countries; consideration includes third-party service provider payments and $75,000 per month payments to Sermonix

Open in proxy
Sermonix Pharmaceuticals, Inc.
an affiliate of Perceptive Advisors held approximately 29% of the outstanding capital stock of Sermonix at the time of entry into the Sermonix License
Amount not stated
December 18, 2025

Securities purchase agreement under which we issued a pre-funded warrant to purchase 5,502,402 shares of common stock at an exercise price of $0.001 per share, with related registration rights

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans